Viking Therapeutics

VKTX55

$54.13arrow_drop_down2.27%-$1.26

VKTX55

$54.13

arrow_drop_down2.27%-$1.26

Performance History

Key Stats
Open	$57.59
Prev. Close	$58.10
EPS	-0.93
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	54.51	58.38
52 Week Range	8.28	99.41

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-0.93

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Viking Therapeutics (VKTX)

Viking Therapeutics Inc (VKTX) is a biopharmaceutical company focused on the development of therapies for metabolic and endocrine disorders. The company's lead candidate is VK2809, an orally available small molecule thyroid hormone receptor beta agonist that is being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and dyslipidemia. NASH is a chronic liver disease that is characterized by the accumulation of fat in the liver, leading to inflammation and fibrosis. It is estimated that NASH affects up to 5% of the global population and is a leading cause of liver cirrhosis and hepatocellular carcinoma.

In recent news, Viking Therapeutics Inc announced positive results from a Phase 2 study of VK2809 in patients with biopsy-confirmed NASH. The study demonstrated a statistically significant reduction in liver fat content compared to placebo, as well as improvements in key markers of liver health. These results support the potential of VK2809 as a novel treatment for NASH, a disease for which there are currently no approved therapies. The company is now preparing for a Phase 3 clinical trial of VK2809 in NASH patients.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Brian Lian Ph.D.
Headquarters: San Diego
Employees: 22
Exchange: NASDAQ

Keep an eye on Viking Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Viking Therapeutics 's (VKTX) price per share?

The current price per share for Viking Therapeutics (VKTX) is $54.13. The stock has seen a price change of -$1.26 recently, indicating a -2.27% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Viking Therapeutics (VKTX)?

For Viking Therapeutics (VKTX), the 52-week high is $99.41, which is 83.65% from the current price. The 52-week low is $8.28, the current price is 553.74% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Viking Therapeutics (VKTX) a growth stock?

Viking Therapeutics (VKTX) has shown an average price growth of 0.41% over the past three years. It has received a score of 98 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Viking Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Viking Therapeutics (VKTX) stock price performance year to date (YTD)?

As of the latest data, Viking Therapeutics (VKTX) has a year-to-date price change of 196.12%. Over the past month, the stock has experienced a price change of 1.5%. Over the last three months, the change has been -1.6%. Over the past six months, the figure is -40.63%. Looking at a longer horizon, the five-year price change stands at 660.25%.

help

Is Viking Therapeutics (VKTX) a profitable company?

Viking Therapeutics (VKTX) has a net income of -$85.9M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$100.83M. Furthermore, the EBITDA is $0.

help

What is the market capitalization of Viking Therapeutics (VKTX)?

Viking Therapeutics (VKTX) has a market capitalization of $6.13B. The average daily trading volume is 2.76M, indicating the stock's liquidity and investor engagement.